Conclusion
We present the first analysis on cost of the implantation of sutureless
valves compared with standard aortic valve prostheses in the United
States and have demonstrated acceptable short-term outcomes. These rapid
deployment valves also facilitate the use of minimally invasive
approaches and result in lower cardiopulmonary bypass and cross-clamp
times, which may be beneficial in older patients and higher-risk
multicomponent operations. We have also demonstrated cost neutrality,
and the decreasing incidence of heart block over time likely due to
changes in implantation technique. We feel this valve offers another
tool for surgeons in an era of TAVR growth.